Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 11/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28258096 | 0.81 | SLC7A5 (0.46) | GRIK1GRIK2SLC7A5SLC1A1SLC1A3 | |
| SCHEMBL28430622 | 0.76 | GRIK1 (0.55) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL19650483 | 0.74 | SLC7A5 (0.38) | SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL2231422 | 0.72 | SLC7A5 (0.58) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL9102865 | 0.72 | SLC7A5 (0.58) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL2679188 | 0.71 | TSHR (0.40) | GRIK1GRIK2 | |
| SCHEMBL29024969 | 0.71 | SLC7A5 (0.68) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL9545322 | 0.71 | SLC7A5 (0.68) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL600881 | 0.71 | SLC7A5 (0.68) | GRIK1GRIK2SLC7A5SLC1A1GRM1 | |
| SCHEMBL4112964 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216758-A1 | CANCER STARVATION THERAPY | SERBIG PHARMACEUTICALS CORP. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216758-A1 | CANCER STARVATION THERAPY | TUFM, TFAM, GFM1 | GRIK1 1613/4885GRIK2 1802/4885SLC7A5 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.